A phase II study of temozolomide in advanced untreated pancreatic cancer

Investigational New Drugs

Volumn 16, Issue 1, 1998, Pages 77-79

  Moore, Malcolm J ^a,b   Feld, Ron ^a   Hedley, David ^a   Oza, Amit ^a   Siu, Lillian L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Department of Medicine ^*  (Canada)

Author keywords

Alkylating agents; Pancreatic cancer; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CYTOTOXICITY; FEVER; HUMAN; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; HUMANS; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0031872387     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006043332368     Document Type: Article

References (9)

1. Stevens MFG, Hickman JA, Stone R, Langdon SP. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazotetrazoneone, a novel drug with potential as an alternative to dacarbazine. Cancer Research 47: 5846-5852, 1987.
2. Tsang LLH Quarterman CP, Gescher A, Slack JA. comparison of cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of MTIC. Cancer Chemother Pharmacol 27: 342-346, 1991.
3. Du DL, Volpe DA, Grieshaber CK, Murphy MJ. In vitro myelotoxicity of 2-3'-dideoxynucleosides on human hematopoietic progenitor cells. Exp Hematol 18: 832-836, 1991.
4. Newlands ES, Blackledge GR, Slack JA, Ruiestin GJ. Phase I trial of temozolomide. Br J Cancer 65: 287-291, 1992.
5. O'Reilly SM, Newlands ES, Glaser MG. Temozolomide, a new oral cytotoxic chemotherapy agent with promising activity against brain tumors. Eur J Cancer 29A: 940-945, 1993
6. Bleehan NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJS, Brampton M, Stevens MFG. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910-913, 1995.
7. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to BCNU. Cancer Research 56: 5375-5379, 1996.
8. 6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74: 1030-1036, 1996.
9. 6-alkylguanine-DNA alkyl-transferase by antitumor triazene compounds. J Pharm Exp Therapeutics 279: 416-422, 1996.